Tirzepatide tied to lower healthcare costs in older adults

Clinical takeaway: Patients on tirzepatide had fewer hospitalizations and ED visits, savings that neared what Medicare pays for the drug by 12 months and exceeded it by 18 months. 

Obesity medicine requires constantly wrestling with the budget question. Now that Medicare's GLP-1 Bridge pilot program subsidizes weight-management incretins for older adults, every prescription raises the question whether the drugs' downstream benefits justify what taxpayers spend on them. Clinicians feel the tension in prior authorizations and coverage denials. Older patients, who stand to gain the most from fewer weight-related complications, are the population where the fiscal stakes run highest. 

More than 30% of US adults over 55 are impacted by obesity. The economics of weight management in this age group have been argued mostly from projections. Modeling studies estimated that Medicare coverage of weight-loss drugs could save billions over decades, but Medicare Part D was barred by statute from covering them for weight loss alone until the Bridge program launched in July 2026, offering tirzepatide, semaglutide, and orforglipron at a net monthly cost of $195 to Medicare, with patients paying a $50 copay. 

What has been lacking is real-world cost evidence in older adults. A new matched claims analysis, the first real-world cost study of tirzepatide in adults over 55, now offers an early answer. The trajectory is promising so far: the longer patients stayed on the drug, the further their costs diverged from untreated peers. 

Among older adults consistently on tirzepatide, monthly healthcare costs excluding the drug itself were 12.3% lower than matched untreated adults' costs during months six through 12, a difference of $145 per patient per month. By months 12 through 18 the gap had grown to 25.4%, or $319 per patient per month. Costs in the tirzepatide group held essentially flat from baseline, while those among untreated adults rose from $1,031 to $1,244 per month over the same period. 

Fewer hospital stays and emergency visits drove the difference between groups. Adults on tirzepatide had a roughly 31% lower rate of inpatient admissions and ED visits relative to baseline than untreated adults during months 12 through 18, with significant reductions at every follow-up window. Routine outpatient and office visits, by contrast, did not change significantly in either direction. A supporting analysis that handled dropout differently produced even larger savings estimates, up to $607 per patient per month by 18 months, making $319 the conservative end of a range rather than a ceiling. 

The study matched 15,843 adults over 55 who started tirzepatide for weight management against as many similar untreated adults in Komodo claims data. All had obesity, or overweight plus a weight-related condition, without diabetes. Follow-up ended at discontinuation, so the findings describe only those who stayed on therapy; fewer than 10% reached the final window behind the largest estimates. Most participants were commercially insured, and the cohort starts a decade younger than the 65-plus group eligible under the Bridge program. Eli Lilly funded the study, and its authors are Lilly employees or contractors. 

The Bridge program is a transitional measure, running through the end of 2027 ahead of a potential broader expansion under the CMS BALANCE model, so the coverage question this study speaks to will likely be determined on that timeline.  

The authors spell out the analyses that remain to be done: an intention-to-treat estimate that counts patients who quit the drug, which they deferred because 2024 supply shortages muddied persistence, and breakdowns by race, ethnicity, and region, which the thin later follow-up windows could not support. Longer claims runway will resolve both of these issues as the post-approval record accumulates. 

"This analysis shows treatment costs can be lowered, and in some cases more than covered, by savings elsewhere in care – including for payers and in Medicare," said Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities. "As coverage expands across Medicare, states and employers, these data offer evidence on the cost implications of long-term obesity treatment and should help shape decisions." 

Source: Upadhyay N, et al. (2026 Aug 26) Diabetes Obes Metab. Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis